Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966559953> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W1966559953 endingPage "284" @default.
- W1966559953 startingPage "277" @default.
- W1966559953 abstract "The important role of ascorbic acid (AA) as an anti-oxidant is particularly relevant in diabetes mellitus where plasma concentrations of AA are reduced. This study was conducted to evaluate the effects of treatment with AA or an aldose reductase inhibitor, tolrestat, on AA metabolism and urinary albumin excretion in diabetes. Blood and urine samples were collected at 0, 3, 6, 9, and 12 months from 20 diabetic subjects who were randomized into two groups to receive either oral AA 500 mg twice daily or placebo. Systolic and diastolic blood pressures, HbA<sub>1c</sub>, plasma lipids, urinary albumin, and total glycosaminoglycan excretion were measured at all time points, and heparan sulphate (glycosaminoglycan) was measured at 0 and 12 months. The same parameters, as well as urinary AA excretion, were determined at 0 and 3 months for 16 diabetes subjects receiving 200 mg tolrestat/day. AA treatment increased plasma AA (ANOVA, F ratio = 12.1, p = 0.004) and reduced albumin excretion rate (AER) after 9 months (ANOVA, F ratio = 3.2, p = 0.03), but did not change the other parameters measured. Tolrestat lowered plasma AA (Wilcoxon’s signed-rank test, p < 0.05), but did not change AER or the other parameters measured. The ability of AA treatment to decrease AER may be related to changes in extracellular matrix or improvement in oxidative defence mechanism. Unlike the rat model of diabetes, inhibition of aldose reductase did not normalize plasma AA or AER in humans. In fact, tolrestat reduced the plasma AA concentration, a phenomenon which may be due to increased utilization of AA. Dietary supplementation of AA in diabetic subjects may have long-term benefits in attenuating the progression of diabetic complications." @default.
- W1966559953 created "2016-06-24" @default.
- W1966559953 creator A5007615278 @default.
- W1966559953 creator A5029925244 @default.
- W1966559953 creator A5049090208 @default.
- W1966559953 creator A5065458452 @default.
- W1966559953 creator A5081864470 @default.
- W1966559953 date "1998-01-01" @default.
- W1966559953 modified "2023-10-13" @default.
- W1966559953 title "Administration of Ascorbic Acid and an Aldose Reductase Inhibitor (Tolrestat) in Diabetes: Effect on Urinary Albumin Excretion" @default.
- W1966559953 cites W2030964542 @default.
- W1966559953 cites W2047288187 @default.
- W1966559953 doi "https://doi.org/10.1159/000045187" @default.
- W1966559953 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9807036" @default.
- W1966559953 hasPublicationYear "1998" @default.
- W1966559953 type Work @default.
- W1966559953 sameAs 1966559953 @default.
- W1966559953 citedByCount "47" @default.
- W1966559953 countsByYear W19665599532012 @default.
- W1966559953 countsByYear W19665599532013 @default.
- W1966559953 countsByYear W19665599532014 @default.
- W1966559953 countsByYear W19665599532015 @default.
- W1966559953 countsByYear W19665599532016 @default.
- W1966559953 countsByYear W19665599532017 @default.
- W1966559953 countsByYear W19665599532020 @default.
- W1966559953 countsByYear W19665599532021 @default.
- W1966559953 countsByYear W19665599532022 @default.
- W1966559953 countsByYear W19665599532023 @default.
- W1966559953 crossrefType "journal-article" @default.
- W1966559953 hasAuthorship W1966559953A5007615278 @default.
- W1966559953 hasAuthorship W1966559953A5029925244 @default.
- W1966559953 hasAuthorship W1966559953A5049090208 @default.
- W1966559953 hasAuthorship W1966559953A5065458452 @default.
- W1966559953 hasAuthorship W1966559953A5081864470 @default.
- W1966559953 hasConcept C10146269 @default.
- W1966559953 hasConcept C126322002 @default.
- W1966559953 hasConcept C134018914 @default.
- W1966559953 hasConcept C185592680 @default.
- W1966559953 hasConcept C2776125364 @default.
- W1966559953 hasConcept C2776439734 @default.
- W1966559953 hasConcept C2777374081 @default.
- W1966559953 hasConcept C2986274086 @default.
- W1966559953 hasConcept C31903555 @default.
- W1966559953 hasConcept C555293320 @default.
- W1966559953 hasConcept C71924100 @default.
- W1966559953 hasConceptScore W1966559953C10146269 @default.
- W1966559953 hasConceptScore W1966559953C126322002 @default.
- W1966559953 hasConceptScore W1966559953C134018914 @default.
- W1966559953 hasConceptScore W1966559953C185592680 @default.
- W1966559953 hasConceptScore W1966559953C2776125364 @default.
- W1966559953 hasConceptScore W1966559953C2776439734 @default.
- W1966559953 hasConceptScore W1966559953C2777374081 @default.
- W1966559953 hasConceptScore W1966559953C2986274086 @default.
- W1966559953 hasConceptScore W1966559953C31903555 @default.
- W1966559953 hasConceptScore W1966559953C555293320 @default.
- W1966559953 hasConceptScore W1966559953C71924100 @default.
- W1966559953 hasIssue "3" @default.
- W1966559953 hasLocation W19665599531 @default.
- W1966559953 hasLocation W19665599532 @default.
- W1966559953 hasOpenAccess W1966559953 @default.
- W1966559953 hasPrimaryLocation W19665599531 @default.
- W1966559953 hasRelatedWork W2006670632 @default.
- W1966559953 hasRelatedWork W2059373368 @default.
- W1966559953 hasRelatedWork W2081402487 @default.
- W1966559953 hasRelatedWork W2084703504 @default.
- W1966559953 hasRelatedWork W2093749606 @default.
- W1966559953 hasRelatedWork W2137351911 @default.
- W1966559953 hasRelatedWork W2143676904 @default.
- W1966559953 hasRelatedWork W2147256274 @default.
- W1966559953 hasRelatedWork W2431483632 @default.
- W1966559953 hasRelatedWork W2748952813 @default.
- W1966559953 hasVolume "80" @default.
- W1966559953 isParatext "false" @default.
- W1966559953 isRetracted "false" @default.
- W1966559953 magId "1966559953" @default.
- W1966559953 workType "article" @default.